Xie WT, Yang H, Bai L, Wu FF. New perspectives and prospects for the next generation of combination therapy in inflammatory bowel disease. World J Gastroenterol 2025; 31(5): 99462 [DOI: 10.3748/wjg.v31.i5.99462]
Corresponding Author of This Article
Feng-Fei Wu, MD, Postdoctoral Fellow, Guangdong Provincial Key Laboratory of Gastroenterology, Institute of Gastroenterology of Guangdong Province, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, No. 1838 Guangzhou Dadao North, Guangzhou 510515, Guangdong Province, China. heison@smu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 7, 2025; 31(5): 99462 Published online Feb 7, 2025. doi: 10.3748/wjg.v31.i5.99462
New perspectives and prospects for the next generation of combination therapy in inflammatory bowel disease
Wen-Ting Xie, Hui Yang, Lan Bai, Feng-Fei Wu
Wen-Ting Xie, Hui Yang, Lan Bai, Feng-Fei Wu, Guangdong Provincial Key Laboratory of Gastroenterology, Institute of Gastroenterology of Guangdong Province, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China
Co-first authors: Wen-Ting Xie and Hui Yang.
Co-corresponding authors: Lan Bai and Feng-Fei Wu.
Author contributions: Xie WT, Bai L, and Wu FF conceptualized and designed the article; Wu FF and Bai L constructed the outline of the article; Xie WT and Yang H authored the manuscript. All the authors have read and approved the final manuscript. Xie WT and Yang H made crucial and indispensable contributions towards the completion of the project and thus qualified as the co-first authors of the article. Wu FF and Bai L have played important and indispensable roles in the construction and revision of the manuscript as the co-corresponding authors. Wu FF secured the funding for the project, overseeing the conceptualization, design, and supervision of the entire project. Bai L was responsible for the comprehensive review and revision of the current manuscript, with a particular focus on the new frontiers of integrated treatment regimens for inflammatory bowel disease. This collaboration between Wu FF and Bai L is crucial for the publication of this manuscript.
Supported by the National Natural Science Foundation of China, No. 82400591 (to Wu FF).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Feng-Fei Wu, MD, Postdoctoral Fellow, Guangdong Provincial Key Laboratory of Gastroenterology, Institute of Gastroenterology of Guangdong Province, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, No. 1838 Guangzhou Dadao North, Guangzhou 510515, Guangdong Province, China. heison@smu.edu.cn
Received: July 23, 2024 Revised: November 23, 2024 Accepted: December 10, 2024 Published online: February 7, 2025 Processing time: 159 Days and 18.2 Hours
Abstract
This article comments on the letter by Lowell et al, which addresses the next generation of combination therapy for inflammatory bowel disease (IBD). As the understanding of the pathogenesis of IBD continues to improve, treatment strategies are evolving rapidly. The letter examines the current status and future directions of combination therapy for IBD, focusing on approaches that combine biologics with immunomodulators and the emerging dual-biologic therapy (DBT). The traditional combination of biologics and immunomodulators has demonstrated preliminary efficacy by enhancing the effects of biologics through immunomodulation. However, concerns regarding long-term safety warrant careful evaluation. Recent trials, including DUET-Crohn's disease and DUET-ulcerative colitis, have shown promising potential for the broader adoption of DBT. Nevertheless, comprehensive data on efficacy and safety, as well as the effective integration of supportive treatments, remain essential to establish new paradigms for the next generation of IBD care.
Core Tip: The treatment strategies for inflammatory bowel disease (IBD) are rapidly evolving with research progress, gradually shifting from the combination therapy of biologics and immunomodulators to the emerging dual-biological therapy. Although dual-biologic therapy has shown the potential for widespread application, establishing a new generation of IBD treatment paradigm still requires comprehensive data support.
